CVD Risk Approach Plan

<table>
<thead>
<tr>
<th>Risk Characterization / Formulation</th>
<th>CM Development / Evaluation</th>
<th>CM Integration/Validation</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVD-101: Determine whether long duration weightlessness induces cardiovascular structural and functional changes and/or oxidative stress and damage (OSaD)/inflammation, that can contribute to development of disease.</td>
<td>CVD-201: Select countermeasures and procedures to be tested based on previous objectives.</td>
<td>CVD-301: Test the integrated countermeasure suite in deep-space missions and on the moon, based on previous tests of countermeasures on the ground and ISS.</td>
</tr>
<tr>
<td>CVD-102: Determine whether space radiation induces cardiovascular structural and functional changes and/or oxidative stress and damage (OSaD)/inflammation, that can contribute to development of disease.</td>
<td>CVD-202: Develop and ground-test countermeasures against the spaceflight-induced changes in the cardiovascular system of importance for development of disease.</td>
<td></td>
</tr>
<tr>
<td>CVD-103: Determine whether the combined effects of relevant deep-space radiation and weightlessness induce additive or synergistic effects on the cardiovascular system, and whether it is of concern for development of disease.</td>
<td>CVD-203: Test countermeasures on the ISS against the spaceflight-induced changes in the cardiovascular system of importance for development of disease.</td>
<td></td>
</tr>
</tbody>
</table>

External Deliverables

- CVD Standards based on weightlessness to OCHMO
- CVD Standards Combined Effects to OCHMO
- CVD CM based on Weightlessness to SCLT/HMTA

Legend:

- Analog
- Flight environment
- Cross Element Integration
- Anticipated PRR Color Change
- SR

Note: Milestones (●) and Gap Closures (●) are Program reviews with defined entry/exit criteria.